AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$EDSA

Edesa Biotech, Inc.

Price · $EDSAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $EDSA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $EDSA in the last 30 days.

Top stories · $EDSAMore →
MAY 15·Stock TitanHigh

Drug data show ARDS treatment benefits as vitiligo trial nears

Edesa Biotech (Nasdaq: EDSA) reported its fiscal Q2 2026 results and provided clinical updates. The company is advancing preparations for a Phase 2 study of EB06 in vitiligo, with site activation and recruitment targeted for mid-2026. Additionally, Edesa reported positive Phase 3 data for paridiprubart in Acute Respiratory Distress Syndrome (ARDS), showing consistent treatment benefits across various severity and comorbidity subgroups.

APR 22·HarianBasis.co

Edesa Biotech Schedules Phase 2 Vitiligo Study for Mid-2026

Edesa Biotech plans to begin enrollment for its Phase 2 clinical study of EB06, a potential treatment for nonsegmental vitiligo, in mid-2026. The company has secured partnerships and initiated site outreach, with patient recruitment expected to start in Canada upon regulatory approval. EB06 targets the CXCL10 chemokine to prevent or reverse depigmentation and has shown biological activity and a favorable safety profile in previous evaluations.

OCT 31·GlobeNewswire

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Edesa Biotech, Inc. ( Nasdaq:EDSA ) , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to ...

News on $EDSA

All news →